Drug Sponsors

Valeant, Pershing Square make revised offer for Allergan

Monday, June 2, 2014 01:07 PM

Valeant Pharmaceuticals International, a multinational specialty pharmaceutical company, has revised its offer for Allergan. Each Allergan share would be exchanged for $72 in cash and 0.83 shares of Valeant common stock, based on the fully diluted number of Allergan shares outstanding. This offer is subject to prompt good faith negotiation of a merger agreement between Valeant and Allergan. 

More... »

WIRB Copernicus Group

Agena Bioscience acquires Sequenom's Bioscience business

Monday, June 2, 2014 01:01 PM

Agena Bioscience, a portfolio company of Telegraph Hill Partners (THP), has acquired the Bioscience business of Sequenom, which sells the MassARRAY System for mass spectrometry-based detection of nucleic acids in research and clinical laboratories.

More... »

CRF Health eCOA webinar series

Senesco completes acquisition of Fabrus

Friday, May 23, 2014 02:34 PM

Senesco Technologies, a clinical stage biotech company specializing in cancer therapeutics, has completed its acquisition of Fabrus, a biotechnology company focused on expanding the clinical impact of antibodies by addressing drug targets resistant to traditional antibody discovery methods.

More... »

Abbott acquires CFR Pharmaceuticals, expanding Latin American presence

Monday, May 19, 2014 01:24 PM

Abbott will acquire Latin American pharmaceutical company CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence.

More... »

AstraZeneca rejects Pfizer’s “final” acquisition offer

Monday, May 19, 2014 12:02 PM

By Ronald Rosenberg
CenterWatch Staff Writer

Barely nine hours after Pfizer made its fourth and “final” takeover offer, raising it to $118 billion, AstraZeneca rejected it today, ending the U.S. pharma giant’s plan to create the world’s largest biopharmaceutical company.

More... »

Bayer to divest interventional device business to Boston Scientific

Friday, May 16, 2014 12:50 PM

Bayer HealthCare will sell its interventional device business to Boston Scientific. The total consideration for the transaction, including fees for transitional services, is $415 million.

More... »

Janssen Labs expands to San Francisco, adds three to @LabCentral

Thursday, May 15, 2014 01:26 PM

Janssen Labs, part of Janssen R&D, plans to open Janssen Labs @South San Francisco, a new 30,000-square-foot, standalone operation based in South San Francisco, Calif. The new location will accommodate up to 50 independent, emerging companies to be co-located with staff from Johnson & Johnson Innovation. Like the flagship Janssen Labs in San Diego, Janssen Labs @South San Francisco will include a combination of shared and private lab and office spaces and feature value-added solutions including operational support, education and business services. Janssen Labs @South San Francisco is scheduled to open at the end of the year.

More... »

Merck sells ophthalmology business to Santen for $600 million

Wednesday, May 14, 2014 01:33 PM

Santen Pharmaceutical has purchased Merck's ophthalmology products in Japan and key markets in Europe and Asia Pacific.

More... »

MabVax Therapeutics, Telik to merge

Wednesday, May 14, 2014 01:22 PM

MabVax Therapeutics, a privately held cancer immunotherapy company, and Telik, a clinical stage oncology drug development company, have agreed to merge. MabVax and Telik will be combined into a publicly traded company focused on the development of proprietary immunotherapy-based products to diagnose and treat cancer. 

More... »

Allergan board unanimously rejects unsolicited offer from Valeant

Monday, May 12, 2014 04:08 PM

Allergan today said its board of directors has unanimously rejected the April 22 unsolicited proposal by Valeant Pharmaceuticals International. After a comprehensive review, conducted in consultation with its financial and legal advisors, the Allergan board concluded the proposal substantially undervalues Allergan, creates significant risks and uncertainties for the stockholders of Allergan and is not in the best interests of the company and its stockholders.

More... »

Subscribe to The CenterWatch Monthly



Browse by:


July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs